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SUMMARY
Background  and  aim  —  Dietary  polyethylene  glycol  (PEG)  is  extraordinarily  potent  in  the 
chemoprevention of experimental colon carcinogenesis. PEG is used to treat constipation in France 
and  in  the  USA.  French  laxatives  include  Forlax®  (PEG4000),  Movicol®  and  Transipeg® 
(PEG3350), and Idrocol® (pluronic F68). This study tests the hypothesis that use of a PEG-based 
laxative might reduce the prevalence of colorectal tumors. 
Methods  —  In  this  population-based  study,  consecutive  patients  attending  for  routine  total 
colonoscopy were enrolled during four months by the gastroenterologists of Indre-et-Loire. They 
were asked if they had previously taken a laxative or a NSAID. Age, gender,  previous polyps, 
family history of colorectal cancer, constipation, digestive symptoms were also recorded.  Tumors 
found during colonoscopy were categorized histologically.
Results — Records from 1165 patients fulfilled the inclusion criteria, 607 women and 498 men, 
mean age 58.3. Among those, 813 had no tumor, 329 had adenomas, and 23 had carcinomas. In a 
univariate analysis, older age, male gender, lack of digestive symptom, and previous polyps were 
more common in patients with colorectal tumors. In contrast, previous Forlax® intake was more 
common in tumor-free patients (odds ratio (OR) any use/no use, 0.52; 95% confidence interval, 
0.27-0.94). More people used Forlax®, which contains a higher dose of PEG than the other PEG-
laxatives, whose ORs were smaller than one, but did not reach significance. In multivariate analysis, 
older age and male gender were associated with higher risk, and NSAIDs use with lower risk, of 
colorectal tumors.
Conclusion — Forlax® users had a halved risk of colorectal tumors in univariate analysis, which 
suggests that PEG may prevent carcinogenesis.
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Introduction — Le polyéthylène glycol  (PEG) administré  par voie orale  prévient  de façon très 
puissante  la  cancérogénèse  colique  expérimentale.  Le  PEG est  utilisé  dans  le  traitement  de  la 
constipation en France et aux USA. En France, le PEG est commercialisé sous les noms de Forlax® 
(PEG4000), Movicol® et Transipeg® (PEG3350), et Idrocol® (pluronic F68). Cette étude a testé 
l’hypothèse  que  l’utilisation  de  l’un  de  ces  PEG  pouvait  réduire  la  prévalence  des  néoplasies 
colorectales.
Patients et méthodes — Dans cette étude de population tous les malades ayant eu une coloscopie 
totale ont été inclus sur une période de 4 mois par les gastroentérologues de l’Indre et Loire. Les 
malades ont été interrogés par questionnaire sur la prise de laxatifs ou d’anti-inflammatoires non 
stéroïdiens.  Âge,  sexe,  antécédents  de polypes  ou de tumeurs,  antécédents  familiaux de cancer 
colorectal,  constipation  et  autres  symptômes  digestifs  ont  été  également  notés.  Les  lésions 
découvertes en coloscopie ont été classées selon l’examen histologique des prélèvements.
Résultats — Au cours des 4 mois, 1165 malades remplissant les critères d’inclusion ont été inclus, 
607 femmes et 498 hommes âgés de 58.3 ans en moyenne. Parmi eux, 813 ne présentaient pas de 
tumeur et 352 une néoplasie colique (329 avaient au moins un adénome et 23 un adénocarcinome). 
En analyse univariée, l’âge, le sexe masculin, l’absence de symptôme digestif et les antécédents de 
polypes coliques étaient plus fréquents chez les malades avec néoplasie colique. En revanche, la 
prise de Forlax®, qui était le PEG le plus utilisé et un des plus fortement dosés, était plus fréquente
chez les malades indemnes (OR = 0.52 ; IC 95 % : 0.27-0.94). En analyse multivariée, l’âge et le 
sexe  masculin  étaient  associés  à  un  risque  plus  élevé  de  néoplasie  colique  tandis  que  la  prise 
d’AINS était associée à une diminution de ce risque.
Conclusion — Les malades utilisant du PEG (Forlax®) ont un risque de néoplasie colique diminué 
de moitié en analyse univariée, suggérant que le PEG pourrait prévenir la carcinogenèse colique.
Introduction
Colorectal  cancer  is  the  leading  cause  of  cancer  death  in  North-American  and  European  non-
smokers. In spite of a very active clinical research, the five-year survival is still close to 50%. Pre-
vention strategies based on epidemiological data and preclinical studies led to large-scale random-
ized studies. Multiple intervention trials with wheat bran, beta-carotene, ursodeoxycholic acid, folic 
acid or vitamins C and/or E supplements, and fat reduction, did not prevent polyp recurrence. By 
contrast, calcium, sulindac, or aspirin did bring a significant benefice, although a modest one. These 
successful  interventions  reduced  polyp  recurrence  by  15  to  35%  [1-5].  New  chemopreventive 
agents are thus needed.
Polyethylene glycol 4000 (PEG), or macrogol, is a watersoluble polymer which is not absorbed or 
metabolized after ingestion, and has no known toxicity. It is given orally for the treatment of chron-
ic constipation [6-14], and was permitted for use for this indication in France in 1996, and in the 
USA and Canada in 2002. PEG has been shown in several animal models to reduce aberrant crypt 
foci  and  to  prevent  azoxymethaneinduced  colorectal  cancer,  with  a  striking  efficacy  [15-17]. 
Against azoxy-methane-induced tumors in rats, only celecoxib is more effective than PEG [18]. No 
agent is more potent than PEG on aberrant crypts foci, but pluronic F68, a PEG-like block-polymer 
[19]. Conflicting results were observed in Min mice, a model for patients with Familial Adenomat-
ous Polyposis: PEG treatment reduced the polyp yield in one study, but increased it in another one 
[20, 21]. PEG inhibits proliferation, and causes apoptosis, in human HT29 colon cancer cells in 
vitro [22, 23]. PEG might thus be a major chemopreventive agent, but its effects on colonic carcino-
genesis in human have not been reported. Before a prevention trial is set up, it is of paramount im-
portance to get observation data, particularly to rule out the possible adverse effect suggested by 
one of the Min mice studies [24].
The aim of this pilot population study was to compare the prevalence of adenoma and colon cancer 
with prescription of PEG at usual therapeutic doses for the treatment of chronic constipation
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Patients and methods
All patients undergoing colonoscopy in the Indre-et-Loire region, performed by a hospital-based or 
private gastroenterologist (Association Gastro 37) between October 2001 and January 2002 were 
asked to complete a questionnaire. Gender, age, reason for colonoscopy (control after polyp or can-
cer treatment, symptoms of gastrointestinal disorder, colon cancer screening), personal and familial 
history of colonic neoplasias, frequency of stools, presence of gastrointestinal symptoms
and ingestion of aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) were recorded for each 
patient. Treatment with PEG for constipation was also investigated by the following questions: “Are 
you constipated and if so what treatment are you receiving?”, “Which drugs are you taking cur-
rently?”, “Have you ever taken Forlax®, Movicol®, Transipeg® or Idrocol®?”. All the parameters 
were compared with the results of the colonoscopy, defined as “positive” by the presence of ad-
enoma and/or cancer confirmed by histology examination. Patients who refused to fill in the ques-
tionnaire, or whose colonoscopy was incomplete or positive but without histological confirmation, 
were excluded from the study.
Having established in a preliminary study that there was a prevalence of PEG treatment in about 
15%, and a prevalence of positive colonoscopy results, in about 20% of patients undergoing colono-
scopy (unpublished personal results), it was decided that 817 patients were required to reveal 50% 
reduction in risk of detection of adenoma or cancer related to PEG ingestion, with a power of 0.80 
and alpha risk of 0.05.
Results
The records of 1165 patients who underwent total colonoscopy and who replied to the questionnaire 
were studied. They were 498 men and 607 women, mean age 58.3 years, whose characteristics are 
summarized in table I. The prevalence of positive colonoscopy was 30%: twenty three (2%) colono-
scopies revealed cancer and 329 (28%) revealed adenoma. Constipation and/or fewer than 3 stools 
passed per week were reported by 35% women and 15% men (gender difference, P < 0.0001), unre-
lated  to  colonoscopy results.  One hundred  thirty-nine  (12%) of  the  patients  had  received PEG 
(17.4% of women and 5.5% of men, P < 0.0001). On univariate analysis (table I) male gender, older 
age, family history of colorectal polyp or cancer, prior colorectal polyp or cancer, and lack of di-
gestive symptoms were significantly more frequent in patients with positive colonoscopy than those 
without.
By contrast, ingestion of Forlax® was more frequent in patients with no lesion and was associated 
with a halved risk of positive colonoscopy (table II). The use of the other PEG-laxatives, of aspirin, 
and of any NSAID, was associated with non significant reduced risk.
In multivariate analysis, older age (OR = 1.04 per year, P = 0.0001) and male gender (OR = 1.6, P = 
0.001) remained associated with higher risk, and NSAIDs use with lower risk (OR = 0.58, P = 
0.015), of colorectal tumors. No other factor, including previous polyp or cancer, constipation, fiber 
intake, aspirin, Forlax® or any PEG-based laxative use, did show a significant effect in the mul-
tivariate logistic regression analysis.
Discussion
Previous Forlax® intake was more common in tumor-free patients and its use was associated with a 
halved risk of colorectal tumors. In this pilot study, the results show for the first time that PEG 
based Forlax® ingestion was associated with 48% reduction in risk of finding adenoma or cancer 
on complete colonoscopy. This effect seems similar to the effects reported with NSAIDs and aspirin 
in epidemiological [25-27] and intervention studies [2-5], but no previous study reported a direct 
comparison of PEG and NSAIDs. In this population, Forlax® use was more protective than aspirin 
use. The significant association observed for Forlax® on univariate analysis was not observed for 
other PEG-based laxatives, nor for the entire group of patients who admitted taking PEG. Although 
non-significant, all the ORs for PEG-based laxatives were smaller than one, which rules out that 
PEG could increase the tumor growth, as suggested by one study in Min mice with APC mutation 
[21, 28].
The mechanism by which PEG can prevent carcinogenesis is not known, because PEG does not be-
long to a class of known preventive agents. Speculated mechanisms include (i) dilution of promot-
ing compounds in the gut lumen due to PEG bulking properties [15], (ii) protection of epithelia 
from irritation and abrasion, by PEG lubricating, coating, and sealing properties [19], (iii) removal 
of cancer cells from tumors by apoptosis. Results from in vitro studies and in vivo observations sug-
gest the removal of cancer cells from tumors be the major mechanism of PEG protection [22, 23, 
29].
The study was based on a patient-completed questionnaire. This method is easy to set up and it 
quickly yielded PEG ingestion data. It is unlikely that non-users did report PEG usage by mistake, 
but likely that some PEG users forgot to report PEG usage. On the other hand, data from the ques-
tionnaire were not precise, and were not validated. Particularly, this survey did not yield reliable in-
formation regarding the duration, quantity, regularity or timing of PEG ingestion. Some patients 
took PEG intermittently, some had ceased treatment as much as several months before the study, or 
had only recently started, suggesting that the number of patients “really” exposed to PEG, i.e. regu-
larly and for a long period of time, was overestimated. These limitations of the questionnaire could 
have led to misestimate the protective effect of PEG-based laxatives.
The absence of significant reduction in risk with brands of PEG other than Forlax® was possibly re-
lated to a lack of power in the study. Indeed, Forlax® was the most frequently used laxative in this 
study. In addition, PEG dose varies from one brand to another, and appears to be among the highest 
in Forlax®. This too may explain the protective effect afforded by Forlax® alone. Last, Idrocol® 
does not contain PEG, but a PEG-like block polymer, pluronic F68. In animal models, pluronic is 
five times more potent than PEG against colon carcinogenesis [19], and here, all Idrocol® users 
were tumor-free (table II).
On multivariate analysis, the reduction in risk in Forlax® or PEG users was not significant, perhaps 
due to an inclusion bias related to the recruitment method. The patients who were included were se-
lected because they were undergoing colonoscopy for follow-up or detection of lesions and not be-
cause they were taking PEG. The risk of a positive result on colonoscopy is lower in women than in 
men in the general population, as shown here [30]. Functional constipation (and thus taking a laxat-
ive such as PEG) is, however, more common in women, as also shown here [31, 32]. Finally, the 
role of constipation in cancer of the colon suggested by certain epidemiological studies remains 
controversial and was not confirmed in this study, but might have been masked by PEG use [33, 
34].
On multivariate analysis NSAIDs use was associated with a significant reduction in the risk of ad-
enoma and cancer, in agreement with previous reports [14-16]. The protective effects of NSAIDs, 
and the bias suggested above, may have reduced the magnitude of PEG effect in this study. Despite 
these factors, a significantly reduced risk of finding adenoma or cancer of the colon was observed 
with Forlax® on univariate analysis. This suggests that the antitumoral effects of PEG in a con-
trolled prospective study of a homogeneous high risk population might in fact be greater than that 
observed with aspirin and NSAIDs in similar experimental conditions [17-19]. Indeed, rat studies 
show that the magnitude of PEG chemopreventive effect is usually greater than that of other known 
chemopreventive agents such as NSAIDs [18].
In conclusion, this pilot study in a population at high risk of colonic lesions shows that it was 50% 
less likely that patients with adenoma or cancer of the colon would receive Forlax® for constipa-
tion, a PEG-based laxative, suggesting a protective role of that PEG affords protection: an interven-
tion trial is needed to prove the link. The intensity of the effect, which was at least comparable to 
that of aspirin [19], and the good tolerance of PEG [1-9], suggest that the protective effects of treat-
ment with PEG should be studied in patients at high risk of colonic lesions, whether they are con-
stipated or not.
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